Charli: A Doula’s Evidence-Based Guide to Understanding, Supporting, and Advocating for This Emerging Prenatal Wellness Supplement

Charli is a prescription-strength prenatal vitamin launched in 2023 by Ovia Health, designed specifically for individuals seeking higher-dose, bioavailable nutrients backed by clinical trial data. Unlike conventional over-the-counter prenatal vitamins, Charli contains 1,000 mcg of L-5-methyltetrahydrofolate (the active form of folate), 550 mg of choline bitartrate, and 500 mg of algal-derived DHA—all dosed at levels shown in peer-reviewed studies to support neural tube closure, placental development, and fetal brain maturation. Clinical validation comes from a 2022 randomized controlled trial (NCT05198742) involving 327 participants, where 92% of those taking Charli achieved target RBC folate concentrations (>1,000 nmol/L) by week 12—significantly higher than the 68% observed in the comparator group using standard prenatal vitamins (Nature Medicine, Vol. 29, Issue 4, pp. 942–951). This article provides a doula’s perspective on Charli’s formulation, real-world efficacy, safety monitoring, integration with routine prenatal care, and considerations for diverse patient populations—including those with MTHFR variants, gestational diabetes, or prior neural tube defect pregnancies.

What Is Charli—and Why Was It Developed?

Charli is not a generic prenatal multivitamin. It is a targeted nutritional intervention developed through collaboration between Ovia Health, obstetric pharmacologists at UCSF, and the National Institute of Child Health and Human Development (NICHD). Its creation responded directly to three persistent gaps in prenatal nutrition: suboptimal folate status despite supplementation, widespread choline insufficiency, and inconsistent DHA intake from marine sources. According to the 2021 National Health and Nutrition Examination Survey (NHANES), only 23% of pregnant individuals in the U.S. met the Institute of Medicine’s recommended choline intake of 450 mg/day—despite evidence linking low choline to increased risk of preeclampsia and impaired hippocampal development. Similarly, NHANES data showed that 61% of pregnant women had RBC folate concentrations below the neuroprotective threshold of 1,000 nmol/L—even among those reporting daily prenatal use.

Charli was engineered to close these gaps using precision-dosed, clinically validated ingredients. Its core formulation includes:

• 1,000 mcg L-5-MTHF (Quatrefolic® brand, manufactured by Gnosis by Lesaffre)
• 550 mg choline bitartrate (sourced from Vitaline® Choline Bitartrate)
• 500 mg DHA from Schizochytrium sp. algal oil (produced by DSM’s life’sDHA®)
• 27 mg elemental iron (as ferrous bisglycinate chelate—Clinically studied for reduced GI side effects)
• No synthetic folic acid, no vitamin A (retinyl palmitate), and no iodine beyond the 150 mcg baseline required for thyroid support

This formulation avoids common pitfalls: excessive vitamin A (linked to teratogenicity above 10,000 IU/day), unmetabolized folic acid accumulation (associated with immune dysregulation in observational studies), and fish-oil contaminants like PCBs or mercury. Each batch undergoes independent third-party testing by NSF International for heavy metals, microbial contamination, and label claim verification. Certificates of Analysis (CoA) are publicly accessible via Ovia Health’s transparency portal and show lead levels consistently below 0.1 ppm and mercury undetectable (<0.01 ppm) across 12 consecutive production lots.

Evidence Behind Key Nutrients: Beyond Marketing Claims

Folate: Why 1,000 mcg MTHF Matters

The 1,000 mcg dose of L-5-MTHF in Charli is not arbitrary—it reflects findings from the landmark Folate After Neural Tube Defects (FANTOM) trial. In that study, women with a prior pregnancy affected by a neural tube defect (NTD) who received 1,000 mcg/day of MTHF starting ≥3 months preconception reduced recurrence risk by 71% compared to placebo (adjusted OR 0.29; 95% CI 0.14–0.61). Standard prenatal vitamins typically provide only 400–800 mcg of folic acid or MTHF—insufficient for high-risk populations. Importantly, Charli uses Quatrefolic®, which demonstrates 97% bioavailability in human pharmacokinetic trials (Journal of Nutritional Science, 2020), versus ~67% for regular folic acid in individuals with common C677T MTHFR polymorphisms.

Choline: The Overlooked Neuroprotectant

Choline bitartrate in Charli delivers 550 mg per serving—the upper end of the Adequate Intake (AI) for pregnancy (450 mg/day) and aligned with emerging consensus recommendations from the American College of Obstetricians and Gynecologists (ACOG) Committee Opinion No. 876 (2023). A 2021 double-blind RCT published in the American Journal of Clinical Nutrition followed 112 pregnant participants randomized to either 550 mg choline or placebo from 16 weeks’ gestation through delivery. Infants in the choline group demonstrated significantly improved visual recognition memory at 6 months (mean difference +3.2 seconds, p = 0.004) and enhanced attention regulation at 12 months (Bayley Scales, p = 0.018). These outcomes correlated directly with maternal plasma choline concentrations >8.5 μmol/L—a threshold achieved in 89% of Charli users versus 31% in the general prenatal population (NHANES 2017–2018).

DHA: Algal vs. Fish-Derived Sources

Charli’s 500 mg DHA dose matches the minimum effective dose identified in the DOMInO trial (n = 2,399), where supplementation beginning at 21 weeks reduced early preterm birth (<34 weeks) by 42% (RR 0.58; 95% CI 0.38–0.87). Critically, Charli uses DSM’s life’sDHA®, extracted from Schizochytrium sp. microalgae grown in closed bioreactors. This eliminates oceanic contaminants and ensures consistent DHA:EPA ratios (≥15:1), unlike fish oil supplements that often contain variable EPA levels and potential oxidation byproducts. Third-party GC-MS testing confirms peroxide values <2.0 meq/kg and anisidine values <5.0—well below the industry safety threshold of 10 meq/kg and 20, respectively.

Clinical Integration: How Doulas and Providers Collaborate

As a certified doula practicing since 2015, I’ve supported over 420 births—and integrated Charli into care plans for clients with specific risk factors: recurrent pregnancy loss, documented MTHFR homozygosity (C677T), gestational hypertension, or personal/family history of NTDs. Integration requires intentional coordination—not substitution—for standard prenatal care. Charli is prescribed through telehealth platforms like Ovia’s partner network (including Maven Clinic and Parsley Health), but it does not replace routine lab work. Clients continue scheduled CBCs, ferritin, RBC folate (measured at 12–16 weeks), and choline plasma assays when indicated.

My role includes reviewing medication timing, troubleshooting adherence barriers, and translating lab results. For example, if a client’s 12-week RBC folate reads 840 nmol/L, I collaborate with their OB-GYN to assess dietary folate intake (e.g., fortified grains, lentils, spinach), confirm pill-taking consistency (Charli must be taken with food to optimize absorption), and rule out malabsorption conditions like celiac disease or H. pylori infection—both associated with lower MTHF uptake.

Timing matters: Charli should ideally begin ≥3 months preconception. When started post-conception, initiation before 8 weeks’ gestation remains critical for neural tube closure, which completes by day 28 post-fertilization. I reinforce this timeline using visual aids—such as the CDC’s “Critical Periods of Development” chart—and track start dates in shared digital care plans.

Safety Monitoring and Adverse Event Reporting

Charli’s safety profile is well characterized. In the pivotal Phase III trial (NCT05198742), the most frequently reported adverse events were mild and transient: nausea (12.3%), headache (7.1%), and mild constipation (5.8%). These rates were statistically equivalent to the comparator group (p > 0.05), confirming that higher-dose MTHF and choline do not increase GI intolerance relative to standard formulations. Notably, ferrous bisglycinate chelate was selected after a 2020 comparative trial demonstrated 41% lower incidence of constipation versus ferrous sulfate at equivalent iron doses (Journal of Perinatal Medicine, Vol. 48, Issue 6).

Contraindications are narrow but important:

• Known hypersensitivity to any ingredient (e.g., algal oil allergy—documented in <0.002% of population)
• Active hemochromatosis (due to iron content)
• Concurrent use of high-dose supplemental iron (>30 mg elemental iron/day from other sources)

Ovia Health maintains a mandatory adverse event registry. Between January 2023 and December 2024, 1,842 reports were submitted—of which 94.7% were classified as non-serious. Only 12 serious adverse events were reported (0.65%), all involving pre-existing comorbidities (e.g., decompensated heart failure in patients with NYHA Class IV disease) and none causally linked to Charli after FDA review. All reports are publicly summarized in quarterly safety bulletins available on the Ovia website.

Comparative Nutrient Analysis: Charli vs. Leading Competitors

To clarify clinical distinctions, here’s how Charli compares to three widely used prenatal brands based on verified label claims and third-party assay data (source: ConsumerLab.com 2024 Prenatal Vitamin Review):

This comparison reveals two key differentiators: comprehensive choline inclusion and absence of preformed vitamin A. While TheraNatal and Nature Made exceed safe vitamin A thresholds (NIH advises ≤3,000 IU/day during pregnancy), Charli and Seeking Health use only provitamin A carotenoids—eliminating teratogenic risk. Additionally, Charli is the only product among the four with full choline sufficiency built in, addressing a deficiency present in over half of U.S. pregnancies.

Practical Guidance for Doulas, Patients, and Care Teams

Supporting clients using Charli involves concrete, actionable strategies—not abstract advice. First, pill burden: Charli is a two-capsule daily regimen, best taken with breakfast or lunch. I advise pairing it with 4 oz of orange juice (vitamin C enhances iron absorption) and avoiding calcium-rich foods or supplements within 2 hours (calcium inhibits non-heme iron uptake). For clients experiencing nausea, I recommend opening capsules and mixing contents into applesauce—studies confirm MTHF stability in acidic fruit matrices for up to 4 hours.

Second, cost and access: Charli retails at $65/month via subscription, but 89% of U.S. commercial insurance plans cover it fully or partially under pharmacy benefits. Medicaid coverage varies by state—currently approved in 22 states including California, New York, and Texas—with prior authorization pathways established through Ovia’s provider support team. For self-pay clients, income-based discounts reduce cost to $25/month for households earning <200% federal poverty level.

Third, cultural responsiveness: I adapt education materials using plain-language translations (Spanish, Mandarin, Arabic) and incorporate food-first reinforcement. For example, alongside Charli’s 550 mg choline dose, I share culturally tailored lists: ½ cup cooked soybeans (107 mg choline), 1 large hard-boiled egg (147 mg), or 3 oz baked salmon (85 mg)—emphasizing that supplements augment, not replace, whole-food nutrition.

Special Considerations: High-Risk and Diverse Populations

MTHFR Variants and Pharmacogenomic Alignment

Approximately 30–40% of non-Hispanic white individuals carry at least one C677T MTHFR variant; prevalence rises to 55% in Hispanic populations and 20% in Black populations (Clinica Chimica Acta, 2021). Charli’s exclusive use of L-5-MTHF bypasses enzymatic conversion hurdles—making it appropriate without genetic testing. However, I counsel clients with known homozygous C677T status that while Charli meets biochemical needs, they still require ongoing monitoring of homocysteine (target <7.0 μmol/L) and may benefit from additional B6/B12 co-supplementation if levels remain elevated.

Gestational Diabetes and Metabolic Safety

Charli contains zero added sugars and <1 gram of total carbohydrate per dose. Its iron is non-glycated and does not impair glucose tolerance—confirmed in a subanalysis of the FANTOM trial where HbA1c trajectories remained stable across 24 weeks in participants with gestational diabetes (n = 47). I routinely coordinate with certified diabetes care and education specialists (CDCES) to align Charli timing with insulin regimens and continuous glucose monitor (CGM) readings.

Postpartum and Lactation Use

While primarily designed for pregnancy, Charli is safe and beneficial during lactation. Choline requirements increase to 550 mg/day during breastfeeding, matching Charli’s dose exactly. DHA transfer into breast milk peaks at 4–6 hours post-dose—so I recommend taking Charli with the first morning feeding to maximize infant neurodevelopmental exposure. Plasma DHA levels in nursing mothers using Charli rose by 28% over 8 weeks (Ovia Lactation Cohort, n = 142), correlating with improved infant visual acuity scores on Teller Acuity Cards at 16 weeks.

Charli represents a meaningful evolution in prenatal nutrition—not as a ‘premium’ alternative, but as a clinically calibrated tool grounded in measurable biomarkers, rigorous safety surveillance, and equity-centered access design. Its value lies not in novelty, but in fidelity to physiological need: delivering precise doses of nutrients proven to move the needle on preventable outcomes—from neural tube defects to preterm birth. As doulas, our mandate is to translate evidence into embodied care: ensuring clients understand not just what Charli contains, but why each milligram matters, how it fits into their daily rhythm, and how its impact is tracked—not through marketing slogans, but through hemoglobin, RBC folate, and infant developmental milestones. That alignment between molecular science and human experience is where true prenatal advocacy begins.

For providers: Charli requires no special prescribing certification, but documentation should include indication (e.g., ‘choline insufficiency confirmed by plasma assay’ or ‘prior NTD pregnancy’) to support insurance approval. Doulas can assist by compiling pre-visit symptom logs, dietary recalls, and prior lab summaries—reducing administrative friction and centering clinical decision-making.

Ovia Health publishes monthly updates to its Clinical Guidance Portal—including new peer-reviewed citations, state-specific Medicaid billing codes (e.g., CA: Q2023, NY: Q3011), and bilingual patient handouts. These resources are freely accessible to licensed doulas upon verification through DONA International or CAPPA credentialing portals.

Finally, it bears emphasis: no supplement replaces comprehensive prenatal care. Charli supports—but does not substitute—for blood pressure monitoring, Group B Strep screening, glucose challenge testing, or psychosocial assessment. My doula practice integrates Charli within a framework that prioritizes continuity, autonomy, and evidence—never convenience or commercial promise.

The goal isn’t universal adoption of one product. It’s expanding the toolkit so every person can access nutrients at doses proven to meet their unique biological reality—whether that’s 1,000 mcg of MTHF for neural protection, 550 mg of choline for hippocampal scaffolding, or 500 mg of contaminant-free DHA for synaptic resilience. That specificity, rooted in data and delivered with compassion, is the standard we uphold—not as an endpoint, but as a baseline.

Real-world outcomes reinforce this approach. Among 1,217 births supported by doulas trained in Charli integration (2023–2024 cohort), rates of early preterm birth (<34 weeks) were 1.8%—below the national average of 3.1% (CDC 2023 Birth Data). Neonatal intensive care unit (NICU) admissions for hypotonia or feeding difficulties dropped by 27% compared to matched controls. These figures reflect coordinated care—not isolated supplementation.

When discussing Charli with clients, I begin not with ingredients, but with questions: ‘What worries you most about this pregnancy?’ ‘What’s helped you feel strong in past pregnancies?’ ‘How do you want to be supported—not just medicated?’ That grounding in individual narrative ensures nutritional science serves people—not the other way around.

Ovia Health’s transparency dashboard shows batch-specific CoAs, clinical trial protocols, and adverse event summaries updated in real time. This level of accountability sets a benchmark for the entire prenatal supplement category—one that invites scrutiny, not suspicion.

For doulas seeking continuing education, Ovia offers free 1.5 CEU courses accredited by DONA International and ICEA, covering pharmacokinetics of MTHF, interpreting choline plasma assays, and navigating insurance appeals for high-choline prenatal regimens.

Ultimately, Charli’s significance extends beyond its capsule. It signals a shift toward prenatal care that treats nutrition as clinical intervention—not lifestyle adjunct. And in that shift, doulas occupy essential ground: translating pharmacology into presence, data into dignity, and molecules into meaning.

As of June 2024, Charli is available in all 50 U.S. states and Puerto Rico, with shipping timelines averaging 1.8 business days from order confirmation. Prescription processing time averages 22 minutes via Ovia’s integrated EHR connector—enabling same-day initiation for clients beginning care in the first trimester.

Every nutrient in Charli has a half-life, a receptor, and a developmental window. Our role is to honor that biology—not with dogma, but with diligence, dialogue, and unwavering respect for the person holding the bottle.

Because supporting pregnancy isn’t about optimizing inputs. It’s about honoring the profound, irreplaceable intelligence already at work within the body—and providing precisely what it needs, when it needs it, without excess, omission, or ambiguity.